P
Peter A.S. Johnstone
Researcher at Indiana University
Publications - 292
Citations - 9435
Peter A.S. Johnstone is an academic researcher from Indiana University. The author has contributed to research in topics: Radiation therapy & Cancer. The author has an hindex of 48, co-authored 265 publications receiving 8324 citations. Previous affiliations of Peter A.S. Johnstone include Emory University & University of California, San Diego.
Papers
More filters
Journal ArticleDOI
Stereotactic body radiotherapy for primary hepatocellular carcinoma.
David L. Andolino,Cynthia S. Johnson,Mary A. Maluccio,Paul Y. Kwo,A. Joseph Tector,Jennifer Zook,Peter A.S. Johnstone,Higinia R. Cardenes +7 more
TL;DR: SBRT is a safe, effective, noninvasive option for patients with HCC ≤6 cm and should be considered when bridging to transplant or as definitive therapy for those ineligible for transplant.
Journal ArticleDOI
Lymphedema: A primer on the identification and management of a chronic condition in oncologic treatment
TL;DR: In this review, many of the important aspects of lymphedema with which clinicians who treat cancer patients should be familiar are outlined, including the anatomy, pathophysiology, diagnosis, and management of this condition.
Journal ArticleDOI
A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study
Jacob G. Scott,Anders Berglund,Michael J. Schell,Ivaylo B. Mihaylov,William J. Fulp,Binglin Yue,Eric A. Welsh,Jimmy J. Caudell,Kamran Ahmed,Tobin S Strom,Eric A. Mellon,Puja Venkat,Peter A.S. Johnstone,John A. Foekens,Jae K. Lee,Eduardo G. Moros,William S. Dalton,Steven A. Eschrich,Howard McLeod,Louis B. Harrison,Javier F. Torres-Roca +20 more
TL;DR: A GARD-based clinical model could allow the individualisation of radiotherapy dose to tumour radiosensitivity and could provide a framework to design genomically-guided clinical trials in radiation oncology.
Journal ArticleDOI
Phase i feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma
Higinia R. Cardenes,Tracy R. Price,Susan M. Perkins,Mary A. Maluccio,Paul Y. Kwo,Tim Breen,Mark A. Henderson,Tracey E. Schefter,Kathy Tudor,Jill Deluca,Peter A.S. Johnstone +10 more
TL;DR: SBRT is a non-invasive feasible and well tolerated therapy in adequately selected patients with HCC and the preliminary local control and survival are encouraging.
Journal ArticleDOI
Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy.
Christopher J. Kane,Christopher J. Kane,Christopher L. Amling,Christopher L. Amling,Peter A.S. Johnstone,Peter A.S. Johnstone,Nali Pak,Raymond S. Lance,Raymond S. Lance,J. Brantley Thrasher,J. Brantley Thrasher,John P. Foley,Robert H. Riffenburgh,Judd W. Moul,Judd W. Moul +14 more
TL;DR: Patients with biochemical recurrence after radical prostatectomy have a low probability of a positive bone scan (9.4%) or a positive CT scan (14.0%) within 3 years of biochemicalRecurrence.